A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

To join this study, you would need to be a child or young person between 2 and 17 years old with moderate to severe Crohn's disease. This means your Crohn's is currently quite active and has been confirmed by medical tests like an endoscopy. It's also important that other typical treatments for Crohn's haven't worked well for you, or you couldn't tolerate them.

There are certain reasons why someone might not be able to join. For example, if you have a rare genetic condition called hereditary fructose intolerance, or if you've had a bad reaction to similar medicines before. The study also cannot accept participants who have other severe gut conditions, certain immune problems, or active complications of Crohn's that might need surgery soon, like an abscess. Also, if you've had a lot of bowel surgeries or a recent one, this might mean you can't take part.

If you decide to take part, you'll have regular visits to a hospital or clinic. Initially, you'll receive the study medicine through a drip into a vein for 12 weeks. After that, for about a year, you'll usually switch to receiving the medicine as an injection under the skin. Some participants might continue receiving the medicine for up to four more years, depending on how they respond.

Throughout the study, doctors and nurses will do various checks to see how you're doing. This will include medical examinations, blood tests, and asking you to fill out questionnaires about how you're feeling and your symptoms. The study involves close medical attention and regular check-ups to make sure the treatment is safe and effective. The total time you'd be involved in the study, including follow-up after treatment, could be several years.